PTEN and glioma: Glioma research has already seen the clinical impact of high-dimensional of the tumor tissue and its immune components on classical biomarkers; for example, the cytologically diagnosable 10q23 deletion as a biomarker of tumor etiology and prognosis preceded elucidation of the tumor suppressor functions of PTEN and their cross-talk with glioma-specific growth pathways.